**Review Article**

**Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis**

Marc El Beaino, Daniel C. Jupiter, Tarek Assi, Elie Rassy, Alexander J. Lazar, Dejka M. Araujo, and Patrick P. Lin

1Department of Orthopaedic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Department of Orthopaedic Surgery and Rehabilitation Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY, USA
3Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, USA
4Department of Orthopaedic Surgery and Rehabilitation, University of Texas Medical Branch, Galveston, TX, USA
5Department of Cancer Medicine, Gustave Roussy Institute, F-94805 Villejuif, France
6Departments of Pathology & Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
7Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence should be addressed to Patrick P. Lin; plin@mdanderson.org

Received 27 September 2019; Accepted 6 January 2020; Published 29 January 2020

Academic Editor: Quincy Chu

Copyright © 2020 Marc El Beaino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Synovial sarcoma can present morphologically in multiple forms, including biphasic and monophasic subtypes. As a result, the histological diagnosis can sometimes be challenging. Transducin-Like Enhancer 1 (TLE1) is a transcriptional corepressor that normally is involved in embryogenesis and hematopoiesis but is also expressed in certain tumors. This systematic review examines the potential role of TLE1 as a diagnostic biomarker for the synovial sarcoma.

**Materials and Methods.** A literature review and meta-analysis were conducted using the electronic databases Pubmed, the Cochrane Library, and Google Scholar. Thirteen studies met our eligibility criteria and were selected for in-depth analysis. Results. The mean sensitivity and specificity of TLE1 in detecting synovial sarcoma were 94% (95% CI 91–97%) and 81% (95% CI 72–91%), respectively, when all studies were aggregated together. The mean positive predictive value (PPV) of TLE1 was 75% (95% CI 62–87%), whereas the negative predictive value (NPV) was 96% (95% CI 93–98%). Conclusion. TLE1 is a sensitive and specific marker for synovial sarcoma that can aid in its diagnosis. Due to its involvement in several relevant signaling pathways, TLE1 might have direct relevance to the pathophysiology of the disease.

**1. Introduction**

Synovial sarcoma is a translocation-associated soft-tissue tumor that can arise at any age and in any anatomic location [1, 2]. It is driven by oncogenes involving the SS18 gene on chromosome 18 with an SSX partner on chromosome X, frequently SSX1 and SSX2, and rarely SSX4 [3]. Synovial sarcoma can be morphologically classified into three main categories: the monophasic type predominantly composed of fascicles of spindle-shaped cells (Figure 1(a)), the biphasic subtype characterized by variable areas of spindle cells and glandular-like epithelium (Figure 1(b)), and poorly differentiated synovial sarcoma commonly including sheets of small blue round cells [4].

Diagnosis of synovial sarcoma is based on a combination of findings, including its characteristic morphology, immunohistochemical profile, and identification of the driver translocation [5]. Despite being the gold standard in establishing diagnosis, SS18-SSX detection can be challenging in rare cases, since some tumors (<2% of cases) can be driven by other less common cryptic and genetic rearrangements [6–8]. Another diagnostic challenge is the fact that several mesenchymal and nonmesenchymal neoplasms can exhibit morphological features similar to those of...
Synovial sarcoma. The current immunohistochemical biomarkers used in such cases are valuable, but are limited by their specificities and sensitivities [9–11]. There is therefore a need to identify and develop new, reliable markers that can aid in the diagnosis of this tumor.

The Transducin-Like Enhancer (TLE) of split genes encode human transcriptional corepressors that are involved in embryogenesis and hematopoiesis [12, 13]. Gene expression profiling studies have consistently shown the TLE family of genes, TLE1 in particular, to be overexpressed in the nuclei of synovial sarcoma cells [14, 15] (Figure 1(c)). Several immunohistochemical studies, involving whole-tissue sections or tissue microarrays, have analyzed the sensitivity and specificity of TLE1 in this disease [16–28]. Despite some inconsistent results, this marker seems to have notable utility in guiding pathologists in their differential diagnosis. We therefore sought to conduct a meta-analysis with the goal of assessing the value of TLE1 as a diagnostic marker for synovial sarcoma.

2. Materials and Methods

Pubmed, the Cochrane Library, and the Google Scholar databases (updated to May 2, 2019) were systematically searched for studies regarding the diagnostic value of TLE1 in synovial sarcoma. The search syntax used included the keywords “TLE1” OR “TLE-1” AND “synovial sarcoma,” and the search was restricted to English language and to human subject studies. Retrieved articles’ titles and abstracts were examined and then checked for eligibility. The following inclusion criteria were used to identify studies for further analysis: (1) full-text publication evaluating TLE1 as a diagnostic biomarker in synovial sarcoma; (2) presented data including sample sizes of synovial and nonsynovial sarcomas samples; and (3) description of immunohistochemical methods used to detect and measure TLE1 expression. Conference abstracts, comments, and case reports were excluded, as were studies performed on cell lines rather than samples of suspected tumor.

All data were independently abstracted in duplicate by two investigators (MEB and TA) according to the inclusion criteria. Information retrieved from each publication included the first author’s name, year of publication, antigen retrieval method (temperature, buffer, and pH), TLE1 antibody specifications (clonality, species, manufacturer, and dilution), number of cases of synovial sarcoma and mimics, histologic diagnosis, and grading system for TLE1 expression, as well as the sensitivity, specificity, positive, and negative predictive values of TLE1 for synovial sarcoma (or data from which these measures could be derived). Authors were contacted in case missing data were not reported in their respective articles.

Statistical analyses were performed using the metafor package within R (R Core Team, R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/) [29]. Sensitivity and specificity, as well as positive and negative predictive values were all computed with 95% confidence intervals (CI). Random effect models were used to account for interstudy variability, which was summarized with the $I^2$ and $Q$ statistics. Forest and funnel plots were
drawn to summarize results and assess for systematic bias, respectively. Various sensitivity analyses were performed. First, we examined all studies. Next, we examined only studies that used either one of the two most commonly used immunohistochemical scoring methods and then separately examined studies using only one of those methods. We observed that one paper (by Chuang et al. [18]) presented results using both of these methods: we included the appropriate data from this paper that were applicable to our subanalyses.

3. Results

Based on their titles and abstracts, sixteen relevant citations evaluating TLE1 as a diagnostic marker in synovial sarcoma were identified in our literature query. Three articles were excluded from the subsequent analysis since they were non-English, did not include synovial sarcoma in their data, or were excluded from the subsequent analysis since they were non-English. The remaining thirteen publications were selected for further evaluation. After full-text reading, all thirteen articles met our eligibility criteria and were included in our meta-analysis. The included studies’ characteristics are summarized in Table 1.

The mean sensitivity and specificity of TLE1 in detecting synovial sarcoma were 94% (95% CI 91%–97%) and 81% (95% CI 72%–91%), respectively, when all studies were aggregated together, regardless of the immunohistochemical grading system used to measure the marker’s expression. The mean positive predictive value (PPV) of TLE1 was 75% (95% CI 62%–87%), whereas the negative predictive value (NPV) was 96% (95% CI 93%–98%). These values were similar to the ones computed in our subgroup analyses restricted to the grading systems 1 or 2, the two systems that were most commonly relied upon for TLE1 expression measurement (Table 2). However, all diagnostic metrics were slightly higher in the second system, when compared with the first.

Seven studies used a cut-off of 2+ to consider a TLE1 expression positive, regardless of the immunohistochemical grading system [17, 18, 21, 22, 25–27]. This prompted us to utilize this criterion to perform another subanalysis. In such cases, TLE1 sensitivity increased to 97% (95% CI 95%–100%), while its specificity decreased to 73% (95% CI 57%–89%) (Figure 2). The PPV and NPV remained similar to what we had already seen, with values of 74% (95% CI 58%–89%) and 94% (95% CI 88%–100%), respectively.

4. Discussion

Synovial sarcoma is a soft-tissue malignancy that can be histologically classified into three different subtypes: (1) monophasic, composed of spindle-shaped cells; (2) biphasic, encompassing spindle-shaped cells and glandular-like areas; and (3) poorly differentiated, characterized mainly by sheets of small round cells [4]. The diagnosis of synovial sarcoma is not always straightforward in that the monophasic and poorly differentiated subtypes can sometimes be very difficult to distinguish from other mesenchymal and non-mesenchymal tumors, such as fibrosarcoma or undifferentiated pleomorphic sarcomas. Biomarkers that are being currently used in clinical practice to guide pathologists in the differential diagnosis have limited diagnostic value [9–11].

The majority of synovial sarcomas are driven by an SS18-SSX translocation, which fuses the SS18 gene on chromosome 18 with an SSX gene on chromosome X. The sensitivity and specificity of this oncoprotein in detecting synovial sarcoma have been established, which makes its detection crucial to establish the diagnosis [3, 33]. Nine SSX genes

---

**Table 1: Eligible studies’ characteristics.**

| # | Year | Antibody type | Dilution | Buffer | pH | T (°C) | Grading system* | SS sample | NSS sample | Entire sample |
|---|------|----------------|----------|--------|-----|--------|-----------------|-----------|------------|-------------|
| [16] | 2015 | Rabbit polyclonal | 1:200 | PBS | 7.2 | NR | 1 | 74 | 72 | 146 |
| [17] | 2016 | Mouse polyclonal | 1:150 | Citrate | 6 | 95 | 2 | 26 | 7 | 33 |
| [18] | 2013 | Rabbit polyclonal | 1:25 | EDTA | 9 | 95 | 1, 2, 4 | 50 | 85 | 135 |
| [19] | 2011 | Rabbit polyclonal | 1:400 | Citrate | 6 | 97 | 3 | 73 | 139 | 212 |
| [20] | 2016 | Rabbit polyclonal | 1:100 | EDTA | 6 | 95 | 2 | 62 | 322 | 384 |
| [21] | 2009 | Rabbit polyclonal | 1:20 | EDTA | 8.4 | ND | 2 | 35 | 73 | 108 |
| [22] | 2010 | Rabbit polyclonal | 1:100 | EDTA | 8.4 | 95 | 4 | 259 | 60 | 319 |
| [23] | 2009 | Rabbit polyclonal | 1:100 | EDTA | 8 | 97 | 1 | 20 | 143 | 163 |
| [24] | 2011 | Rabbit polyclonal | 1:20 | EDTA | 8 | 95 | 6 | 15 | 25 | 40 |
| [25] | 2012 | Rabbit polyclonal | 1:250 | EDTA | 8 | 97 | 1 | 42 | 69 | 111 |
| [26] | 2017 | Mouse monoclonal | NR | Citrate | NR | 92 | 7 | 10 | 12 | 22 |
| [27] | 2007 | Rabbit polyclonal | 1:20 | EDTA | 8 | 95 | 2 | 94 | 602 | 696 |
| [28] | 2013 | Rabbit polyclonal | 1:100 | EDTA | 6 | 95 | 5 | 5 | 37 | 42 |

Abbreviations: SS: synovial sarcoma; NSS: nonsynovial sarcoma; PBS: phosphate-buffered saline; EDTA: ethylenediaminetetraacetic acid; NR: not reported; ND: no details. * Grading system 1: 0 (<5% of cells positive); 1 (5–25% of cells positive); 2 (25–50% of cells positive); 3 (>50% of cells positive); Grading system 2: 0 (staining not visible); 1 (<26% of cells positive); 2 (26–50% of cells positive at 40x or >50% at 100x objectives); 3 (>50% of cells positive at 40x); Grading system 3: 0 (staining not visible); 1 (<5% of cells positive); 2 (6–25% of cells positive); 3 (26–50% of cells positive); 4 (51–75% of cells positive); 5 (>75% of cells positive); Grading system 4: 0 (no staining); 1 (<10% of cells positive); 2 (11–50% of cells positive); 3 (51–80% of cells positive); 4 (>80% of cells positive); Grading system 5: >20% of cells positive; Grading system 6: 0 (negative); 1 (weak); 2 (moderate); 3 (strong); Grading system 7: 0 (negative); 1 (5–25% of cells positive); 2 (25–50% of cells positive); 3 (50–75% of cells positive); 4 (>75% of cells positive); 5 (>90% of cells positive).
(SSX1–9) have been identified to date, but the contribution of each to synovial sarcoma remains unclear [34]. The most common SS18 fusion partners include SSX1, SSX2, and rarely SSX4. However, some tumors may not exhibit the pathognomonic translocation, and may therefore stem from alternative genetic or cryptic anomalies [6–8]. Such cases underscore the need for a robust array of diagnostic tools capable of confirming the diagnosis of synovial sarcoma while ruling out other potentially confounding tumors.

TLE1 is a member of the TLE family of genes that encode Groucho-like transcriptional co-repressors and is one of the most frequently overexpressed genes in synovial sarcoma [14, 15, 35, 36]. TLE1 binds other basic helix-loop-helix (bHLH) proteins to repress target genes [37–39]. Of these target genes, T-Cell Factor/Lymphoid Enhancer Factor (TCF/LEF), Hairy and Enhancer of Split (HES), and Homeobox proteins (NKX) constitute key mediators of the Wnt/β-catenin, Notch, and Sonic Hedgehog pathways, respectively. Several other genes pertaining to these networks may be dysregulated in synovial sarcoma, including LEFI, AXIN2, TCF7, and FZD homologues in the Wnt/β-catenin, HES1, and NOTCH1 in the Notch, as well as SMO and PTCH in the Sonic Hedgehog pathways [15, 36, 40, 41]. By competing with and dislodging β-catenin and other coactivators from their respective transcriptional activator complexes, TLE1 interacts with bHLH corepressor proteins to generate inhibitor entities that suppress gene transcription [37–39, 42]. Moreover, it alters histone deacetylase activity, which has been shown to be relevant in synovial sarcoma and alters epigenetic signals through transcriptional mediators [43–46]. For example, the Activating Transcription Factor 2 (ATF2) binds to SS18-SSX and redirects it to ATF2-related promoters to induce their corresponding genes’ transcription; however, in the presence of TLE1, SS18-SSX will be displaced and ATF2 target genes repressed [47].

### Table 2: TLE1 diagnostic metrics in our subgroup analyses.

| System | Sensitivity | Specificity | PPV | NPV |
|--------|-------------|-------------|-----|-----|
| 1      | 92% (CI 83%–100%) | 74% (CI 53%–95%) | 64% (CI 34%–93%) | 96% (CI 92%–100%) |
| 2      | 95% (CI 89%–100%) | 88% (CI 82%–94%) | 74% (CI 58%–91%) | 99% (CI 98%–100%) |

(a)

(b)

(c)

(d)

**Figure 2:** Sensitivity and specificity of TLE1 for synovial sarcoma. When limited to the studies that used a 2+ cut-off criterion as a positive TLE1 expression, forest plots detected a (a) sensitivity of 97% and a (c) specificity of 73%. Funnel plots were drawn to assess the systematic bias regarding both the sensitivity (b) and the specificity (d) of TLE1 in synovial sarcoma.
In spite of the variable data regarding the diagnostic value of TLE1 in synovial sarcoma, our analysis indicates that the preponderance of evidence favors TLE1 as a legitimate biomarker for this disease. Due to its high sensitivity and specificity, absence or presence of TLE1 on histology will aid in excluding or confirming the diagnosis of synovial sarcoma. Its high positive and negative predictive values are also beneficial attributes since synovial sarcoma is a rare disease. In particular, our study supports the experience of many clinical laboratories of pathology in that the degree of nuclear reactivity affects the interpretation of this assay. Of note, though TLE1 alone is not sufficient for diagnosis of synovial sarcoma since it is present in other tumors, particularly peripheral nerve sheath tumors that would include schwannomas (100%), neurofibromas (30%), and malignant peripheral nerve sheath tumor (30%) [23], these entities can usually be distinguished from synovial sarcoma on the basis of morphology and other criteria.

There is a number of limitations to our analysis. The lack of a consistent grading system for immunohistochemical staining to quantify TLE1 expression made it difficult to compare results across studies. Several studies did not report data regarding the synovial sarcoma subtypes that were analyzed [18, 20, 22, 23, 25–28]. Others lacked details about the control group to which synovial sarcomas were compared [17, 28]. A particular study compared TLE1 and NKX2.2 expression only in synovial and Ewing sarcomas [26]. Some authors used multiple antibodies to detect TLE1, while others used different techniques in the same study [21, 27]. Terry et al. used both a TLE1 monoclonal and a TLE1 rabbit polyclonal antibody in their analysis [27]. Jagdis et al. reported their combined experience at two different institutions, in which one group used a cold antigen retrieval method, whereas the group at the other institution relied on a heat-induced antigen retrieval technique [21]. Nevertheless, our subgroup analysis did not reveal any substantive differences between the groups of studies relying on different histological systems; this justifies our including all retrieved articles in the same analysis. Based upon our analysis of the different sensitivities and specificities of the various scoring systems, we recommend using a 2+ cut-off to qualify as positive TLE1 staining and Grading System 2 (see Tables 1 and 2).

In conclusion, TLE1 is a sensitive and specific marker for synovial sarcoma that can aid in its diagnosis. Due to its involvement in several relevant signaling pathways in this disease, TLE1 might have direct relevance to the pathophysiology of the disease. Identification of the networks in which TLE1 is involved, from a molecular standpoint, may help develop further diagnostic tests and novel targeted therapies for synovial sarcoma.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper. No benefits in any form have been received from a commercial party related directly or indirectly to the subject of this article.

References

[1] S. K. Machen, K. A. Easley, and J. R. Goldblum, “Synovial sarcoma of the extremities: a clinicopathologic study of 34 cases, including semi-quantitative analysis of spindled, epithelial, and poorly differentiated areas,” The American Journal of Surgical Pathology, vol. 23, no. 3, pp. 268–275, 1999.

[2] M. van de Rijn, F. G. Barr, Q.-B. Xiong, M. Hedges, J. Shipley, and C. Fisher, “Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features,” The American Journal of Surgical Pathology, vol. 23, no. 1, pp. 106–112, 1999.

[3] M. Ladanyi, “Fusions of the SYT and SSX genes in synovial sarcoma,” Oncogene, vol. 20, no. 40, pp. 5755–5762, 2001.

[4] L. Guillou, J. Benhattar, F. Bonichon et al., “Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis,” Journal of Clinical Oncology, vol. 22, no. 20, pp. 4040–4050, 2004.

[5] M. El Beaino, D. M. Araujo, A. J. Lazar, and P. P. Lin, “Synovial sarcoma: advances in diagnosis and treatment identification of new biologic targets to improve multimodal therapy,” Annals of Surgical Oncology, vol. 24, no. 8, pp. 2145–2154, 2017.

[6] A. A. Sandberg and J. A. Bridge, “Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma,” Cancer Genetics and Cytogenetics, vol. 132, no. 1, pp. 1–13, 2002.

[7] J. Przybyl, R. Sciot, P. Rutkowski et al., “Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases,” Tumor Biology, vol. 33, no. 6, pp. 2245–2253, 2012.

[8] C. T. Storlazzi, F. Mertens, N. Mandahl et al., “A novel fusion gene, SS18L1/SSX1, in synovial sarcoma,” Genes, Chromosomes and Cancer, vol. 37, no. 2, pp. 195–200, 2003.

[9] L. J. Jorgensen, “Synovial sarcoma. An immunohistochemical study of the epithelial component,” APMS, vol. 102, no. 3, pp. 191–196, 1994.

[10] C. Fisher, E. Montgomery, and V. Healy, “Calponin and h-caldesmon expression in synovial sarcoma: the use of calponin in diagnosis,” Histopathology, vol. 42, no. 6, pp. 588–593, 2003.

[11] K. Kohashi, Y. Oda, H. Yamamoto et al., “Reduced expression of SMARCB1/INI1 protein in synovial sarcoma,” Modern Pathology, vol. 23, no. 7, pp. 981–990, 2010.

[12] T. E. Swingler, K. L. Bess, J. Yao, S. Stifani, and P.-S. Jayaraman, “The proline-rich homeodomain protein recruits members of the Groucho/transducin-like enhancer of split protein family to co-repress transcription in hematopoietic cells,” Journal of Biological Chemistry, vol. 279, no. 33, pp. 34938–34947, 2004.

[13] J. Yao, “Disrupted development of the cerebral hemispheres in transgenic mice expressing the mammalian groucho homologue transducin-like-enhancer of split 1 in postmitotic neurons,” Mechanisms of Development, vol. 93, no. 1-2, pp. 105–115, 2000.

[14] K. Baird, S. Davis, C. R. Antonescu et al., “Gene expression profiling of human sarcomas: insights into sarcoma biology,” Cancer Research, vol. 65, no. 20, pp. 9226–9235, 2005.

[15] N. H. Segal, P. Pavlidis, C. R. Antonescu et al., “Classification and subtype prediction of adult soft tissue sarcoma by functional genomics,” The American Journal of Pathology, vol. 163, no. 2, pp. 691–700, 2003.

[16] A. Atef and M. Alrashidy, “Transducer-like enhancer of split 1 as a novel immunohistochemical marker for diagnosis of...
synovial sarcoma,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 15, pp. 6545–6548, 2015.

[17] I. H. Bakrin, F. A. Hussain, and S. E. Tuan Sharif, “Transducer-like enhancer of split 1 (TLE1) expression as a diagnostic immunohistochemical marker for synovial sarcoma and its association with morphological features,” The Malaysian Journal of Pathology, vol. 38, no. 2, pp. 117–122, 2016.

[18] H.-C. Chuang, S.-C. Hsu, C.-G. Huang, S. Hsueh, K.-F. Ng, and T.-C. Chen, “Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma,” Pathology International, vol. 63, no. 12, pp. 573–580, 2013.

[19] W. C. Foo, M. W. Cruise, M. R. Wick, and J. L. Hornick, “Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics,” American Journal of Clinical Pathology, vol. 135, no. 6, pp. 839–844, 2011.

[20] X. He, “Diagnostic value of TLE1 for synovial sarcoma: immunohistochemical analyses of genetically confirmed synovial sarcomas and nonsynovial sarcomas,” International Journal of Clinical and Experimental Pathology, vol. 9, no. 4, pp. 4339–4350, 2016.

[21] A. Jagdis, B. P. Rubin, R. R. Tubbs, M. Pacheco, and T. O. Nielsen, “Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma,” The American Journal of Surgical Pathology, vol. 33, no. 12, pp. 1743–1751, 2009.

[22] T. Knösel, S. Heretsch, A. Altendorf-Hofmann et al., “TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t (X; 18): analysis of 319 cases,” European Journal of Cancer, vol. 46, no. 6, pp. 1170–1176, 2010.

[23] K. Kossemehtmetoglu, J. A. Vranca, and A. L. Folpe, “TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms,” Modern Pathology, vol. 22, no. 7, pp. 872–878, 2009.

[24] L. S. Lino-Silva, J. P. Flores-Gutiérrez, N. Vilches-Cisneros, and H. R. Domínguez-Malagón, “TLE1 is expressed in the majority of primary pleuropulmonary synovial sarcomas,” Virchows Archiv, vol. 459, no. 6, pp. 615–621, 2011.

[25] B. Rekhi, “Immunohistochemical validation of TLE1, a novel marker, for synovial sarcomas,” Indian Journal of Medical Research, vol. 136, no. 5, pp. 766–775, 2012.

[26] L. M. Rooper, R. Sharma, C. D. Gocke, and D. A. Belchis, “The utility of NXX2.2 and TLE1 immunohistochemistry in the differentiation of ewing sarcoma and synovial sarcoma,” Applied Immunohistochemistry & Molecular Morphology, vol. 27, no. 3, 2017.

[27] J. Terry, T. Saito, S. Subramanian et al., “TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies,” The American Journal of Surgical Pathology, vol. 31, no. 2, pp. 240–246, 2007.

[28] A. L. Valente, J. Tull, and S. Zhang, “Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma,” Applied Immunohistochemistry & Molecular Morphology, vol. 21, no. 5, pp. 408–413, 2013.

[29] W. Viechtbauer, “Conducting meta-analyses in R with the metafor package,” Journal of Statistical Software, vol. 36, no. 3, p. 48, 2010.

[30] R. J. Mao, “Application of TLE1 expression and fluorescence in-situ hybridization in diagnosing poorly differentiated synovial sarcoma,” Zhonghua Bing Li Xue Za Zhi, vol. 40, no. 6, pp. 403–405, 2011.

[31] D. J. Zaccarini, X. Deng, J. Tull, C. Maciak, A. L. Valente, and S. Zhang, “Expression of TLE-1 and CD99 in carcinoma: pitfalls in diagnosis of synovial sarcoma,” Applied Immunohistochemistry & Molecular Morphology, vol. 26, no. 6, pp. 368–373, 2018.

[32] S. W. Seo, H. Lee, H.-I. Lee, and H.-S. Kim, “The role of TLE1 in synovial sarcoma,” Journal of Orthopaedic Research, vol. 29, no. 7, pp. 1131–1136, 2011.

[33] L. Guillou, J.-M. Coindre, G. Gallagher et al., “Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives,” Human Pathology, vol. 32, no. 1, pp. 105–112, 2001.

[34] A. O. Güre, I. J. Wei, L. J. Old, and Y.-T. Chen, “The SSX gene family: characterization of 9 complete genes,” International Journal of Cancer, vol. 101, no. 5, pp. 448–453, 2002.

[35] G. Chen and A. J. Courey, “Groucho/TLE family proteins and transcriptional repression,” Gene, vol. 249, no. 1-2, pp. 1–16, 2000.

[36] T. O. Nielsen, N. M. Poulin, and M. Ladanyi, “Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy,” Cancer Discovery, vol. 5, no. 2, pp. 124–134, 2015.

[37] D. Grábevec, R. Lo, Y. Liu, and S. Stifi, “Transducin-like enhancer of split 2, a mammalian homologue of drosophila groucho, acts as a transcriptional repressor, interacts with Hairy/Enhancer of split proteins, and is expressed during neuronal development,” European Journal of Biochemistry, vol. 258, no. 2, pp. 339–349, 1998.

[38] B. H. Jennings and D. Ish-Horowicz, “The Groucho/TLE/Grg family of transcriptional co-repressors,” Genome Biology, vol. 9, no. 1, p. 205, 2008.

[39] B. H. Jennings, L. M. Pickles, S. M. Wainwright, S. M. Roe, L. H. Pearl, and D. Ish-Horowicz, “Molecular recognition of transcriptional repressor motifs by the WD domain of the Groucho/TLE corepressor,” Molecular Cell, vol. 22, no. 5, pp. 645–655, 2006.

[40] M. Haldar, J. D. Hancock, C. M. Coffin, S. L. Lessnick, and M. R. Capecci, “A conditional mouse model of synovial sarcoma: insights into a myogenic origin,” Cancer Cell, vol. 11, no. 4, pp. 375–388, 2007.

[41] K. Hayakawa, M. Ikeya, M. Fukuta et al., “Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells,” Biochemical and Biophysical Research Communications, vol. 432, no. 4, pp. 713–719, 2013.

[42] D. L. Daniels and W. I. Weis, “β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation,” Nature Structural & Molecular Biology, vol. 12, no. 4, pp. 364–371, 2005.

[43] G. S. Yochum and D. E. Ayer, “Pf1, a novel PHD zinc finger protein that links the TLE corepressor to the mSin3A-histone deacetylase complex,” Molecular and Cellular Biology, vol. 21, no. 13, pp. 4110–4118, 2001.

[44] L. Arce, K. T. Pate, and M. L. Waterman, “Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression,” BMC Cancer, vol. 9, no. 1, p. 159, 2009.

[45] T. Ito, M. Ouchida, S. Ito et al., “SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex,” Cancer Cell, vol. 8, no. 2, pp. 1484–1490, 2004.

[46] T. Ito, M. Ouchida, Y. Morimoto et al., “Significant growth inhibition of tumours induced by the SYT-SSX fusion oncoprotein inhibitor FK228 in vitro and in vivo,” Cancer Letters, vol. 224, no. 2, pp. 311–319, 2005.

[47] L. Su, A. V. Sampaio, K. B. Jones et al., “Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics,” Cancer Cell, vol. 21, no. 3, pp. 333–347, 2012.